N-Isopropyl-MDA · 3,4-Methylenedioxy-N-isopropylamphetamine
#108 MDIP SYNTHESIS: To a well stirred and cooled solution of 14.75 g isopropylamine in 100 mL MeOH there was added 4.45 g of 3,4-methylenedioxyphenylacetone (see under for its preparation) followed by a 1:1 mixture of concentrated HCl and MeOH, sufficient to bring the pH to about 4. This was followed with 1.1 g sodium cyanoborohydride, and stirring was continued overnight. When the pH increased to over 6 there was added an additional 0.5 g of the borohydride, and additional methanolic HCl was added as needed to maintain the pH there. When the pH became stable, the reaction mixture was brought soundly acid with the addition of yet additional HCl, and all solvents were removed under vacuum. The residues were added to 500 mL H2O and washed with 3×100 mL CH2Cl2. The aqueous phase was made basic with 25% NaOH, and extracted with 4×100 mL CH2Cl2. Removal of the solvent under vacuum yielded 2.8 g of an amber liquid that was distilled at 95–110 °C at 0.3 mm/Hg. There was obtained about 2 mL of a white oil that was dissolved in 10 mL of IPA, neutralized with about 20 drops of concentrated HCl producing spontaneous crystals. These were diluted with some 40 mL of anhydrous Et2O, removed by filtration, washed with Et2O, and then air dried. There was obtained 1.6 g of 3,4-methylenedioxy-N-isopropylamphetamine hydrochloride (MDIP) with a mp of 186–186.5 °C with prior sintering at 185 °C. Anal. (C13H20ClNO2) N.
DOSAGE: greater than 250 mg.
DURATION: unknown.
QUALITATIVE COMMENTS: (with 250 mg) “At 35 minutes there was an extremely slight head disturbance which increased over the next few minutes. I would have missed it if there had been any sensory input at all. At the one hour point there was a slight physical malaise, but no ‘open window’ of any kind, either like or like . At the most, this was a threshold, and in another half hour, I was completely baseline.”
EXTENSIONS AND COMMENTARY: The structure of MDIP can be looked at as exactly that of but with an additional methyl group (one carbon) hanging off the ethyl that is on the nitrogen. And with that slight additional weight, the activity has disappeared. On those occasions where research has shown a compound to be inactive, there has been some study made that could be called a “primer” experiment. Why not take advantage of the fact that an “inactive” compound might well be sitting in some receptor site in the brain without doing anything? Might its presence, wherever it might be, have some effect if only a person were to explore it in the correct way? Might it augment or interfere with the action of another compound? Many experiments of this kind have been performed, geared to milk additional information out of a new trial of a new material.
Here is an example of a primer experiment that involved MDIP. Some five hours following an inactive trial with 120 milligrams of MDIP (maybe a slight disturbance at one hour, nothing at two hours) a calibration dose of 80 milligrams of was taken. The effects of the MDMA were noted at the 33 minute point, and an honest plus one was achieved at one hour. At this point a second 80 milligrams was added to the inventory that was already on board, and the general intoxication and the eye effects that followed were completely explained by the MDMA alone. It was obvious that the two drugs did not see one-another.
Sometimes an experiment can involve the assay of an unknown material at the supplement time of an active drug. This has been called “piggybacking.” Here is an example. At the five hour point of an experiment with 140 milligrams of (this had been a light experience, a plus one which had not laster more than two hours) a dosage of 200 milligrams of MDIP rekindled a +1 experience, a pleasant intoxication of the MDE sort, but one that was quite invested with tremor and some feelings of eye-popping. It was almost as if the physical toxic effects outweighed the mental virtues. Imagine an iceberg, with the bulk of its mass underwater. The MDE had had its own modest effects, and had submerged into invisibility, and the response to a little bit of an otherwise inactive MDIP was to refloat a bit of the otherwise unseeable MDE.
13 May 2016 · Creative Commons BY-NC-SA ·

About PiHKAL · info

This version of Book II of PiHKAL is based on the Erowid online version, originally transcribed by Simson Garfinkle and converted into HTML by Lamont Granquist. I drew also on “Tyrone Slothrop’s” (Unfinished) Review of PIHKAL to enumerate the many analogues mentioned in PiHKAL but not described at length. Many, many others have since been added.
I have tried here to expunge any artifacts introduced by the earlier transcriptions and restore the typographic niceties found in the printed edition. I’ve also made minor changes to some chemical names in line with current nomenclature practice. Typically the change is little more than expanding a prefix or setting it in italics. The history page has further details.

Cautionary note

“At the present time, restrictive laws are in force in the United States and it is very difficult for researchers to abide by the regulations which govern efforts to obtain legal approval to do work with these compounds in human beings.
“No one who is lacking legal authorization should attempt the synthesis of any of the compounds described in these files, with the intent to give them to man. To do so is to risk legal action which might lead to the tragic ruination of a life. It should also be noted that any person anywhere who experiments on himself, or on another human being, with any of the drugs described herein, without being familiar with that drug’s action and aware of the physical and/or mental disturbance or harm it might cause, is acting irresponsibly and immorally, whether or not he is doing so within the bounds of the law.”
Alexander T. Shulgin

Copyright notice

The copyright for Book I of PiHKAL has been reserved in all forms and it may not be distributed. Book II of PiHKAL may be distributed for non-commercial reproduction provided that the introductory information, copyright notice, cautionary notice and ordering information remain attached.

Ordering information

PiHKAL is the extraordinary record of the authors’ years exploring the chemistry and transformational power of phenethylamines. This book belongs in the library of anyone seeking a rational, enlightened and candid perspective on psychedelic drugs.
Though Sasha and Ann have put Book II of PiHKAL in the public domain, available to anyone, I strongly encourage you to buy a copy. We owe them — and there’s still nothing quite like holding a real book in your hands.
PiHKAL (ISBN 0-9630096-0-5) is available for US$24.50 (plus $10 domestic first-class shipping) from Transform Press.
Transform Press,
Box 13675
Berkeley, CA 94701

510 · 934 · 4930 (voice)
510 · 934 · 5999 (fax)